Wilby KJ, Greanya ED, Ford JE, Yoshida EM, Partovi N

Idioma: Ingles.
Referencias bibliográficas: 26
Paginas: 179-185
Archivo PDF: 89.28 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Hepatitis C. World Health Organization. www.who.org [Accessed 2011 Aug 18].

2. Rosen HR. Chronic hepatitis C infection. N Eng J Med 2011; 364: 2429-38.

3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, et al. Peginterferon alfa- 2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001; 358: 958-65.

4. Hadziyannis SJ, Sette H Jr., Morgan TR, Vijayan B, Diago M, Marcellin P, Ramadori G, et al. Peginterferon alfa-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribvirin dose. Ann Intern Med 2004; 140: 346-55.

5. Yoshida EM, Sherman M, Bain VG, Cooper CL, Deschenes M, Marotta PJ, Lee SS, et al. Re-treatment with peginteferon alfa-2a and ribavirin in patients with chronic hepatitis C who have relapsed or not responded to a first course of pegylated interferon-based therapy. Can J Gastroenterol 2009; 23: 180-4.

6. Di Martino V, Rufat P, Boyer N, Renard P, Degos F, Martinot- Peignoux M, Matheron S, et al. The influence of human immunodeficiency virus co-infection on chronic hepatitis C in injection drug users: a long-term retrospective cohort study. Hepatology 2001; 34: 1193-9.

7. Lai JC, Verna C, Brown RS Jr., O’Leary JG, Trotter JF, Forman LM, Durman JD, et al. Hepatitis C virus infected women have a higher risk of advanced fibrosis and graft loss after liver transplantation than men. Hepatology 2011; 54: 418-24.

8. Gludd LL, Marchesini E, Lorio A. Peginterferon plus ribavirin for chronic hepatitis C in patients with human immunodeficiency virus. Am J Gastroenterol 2009; 104: 2335-41.

9. Wang CS, Ko HH, Yoshida EM, Marra CA, Richardson K. Interferon- based combination anti-viral therapy for hepatitis C virus after liver transplantation: a review and quantitative analysis. Am J Transpl 2006; 6: 1586-99.

10. Poordad F, McCone J, Bacon B, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Eng J Med 2011; 364: 1195-206.

11. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, Poordad F, et al. Boceprevir for previously treated chronic HCV genotype 1 infection. N Eng J Med 2011; 364: 1207-17.

12. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, Marcellin P, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Eng J M 2011; 364: 2405-16.

13. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, et al. Telaprevir for retreatment of HCV infection. N Eng J Med 2011; 364: 2417-28.

14. Merck & Co. Victrelis (boceprevir) Product Monograph [Internet]. Whitehouse Station, NJ 2011. Accessed August 5, 2011. Available from: http://www.merck.ca/assets/ en/pdf/products/VICTRELIS-PM_E.pdf

15. Vertex Pharmaceuticals Inc. Incivek (telaprevir) Product Monograph. Cambridge, MA 2011.

16. Kasserra C, Hughes E, Treitel M, Gupta S, O’Mara E. Clinical pharmacology of boceprevir: metabolism, excretion, and drug-drug interactions (abstract 118). 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA [Accessed on 14 Aug 2011]. Available from: http://www.retroconference.org/2011/ Abstracts/41140.htm

17. Ogu CC, Maxa JL. Drug interactions due to cytochrome P450. Proc (Bayl Univ Med Cent) 2000; 13: 421-3.

18. Augustine JJ, Bodziak KA, Hricik DR. Use of sirolimus in solid organ transplantation. Drugs 2007; 67: 369-91.

19. Van Heeswijk RPG, Vandevoorde A, Boogaerts G, Vangeneugden T, de Paepe E, Polo R, Van Solingen-Ristea R, et al. Pharmacokinetic interactions between ARV agents and the investigational HCV protease inhibitor TVR in healthy volunteers (abstract 119). 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA [Accessed on 14 Aug 2011]. Available from: http://www.retroconference.org/2011/Abstracts/ 41437.htm

20. Hariparsad N, Nallani S, Sane R, Buckley DJ, Buckley AR, Desai PB. Induction of CYP3A4 by efavirenz in primary human hepatocytes: comparison with rifampin and Phenobarbital. Clin Pharmacol 2004; 44: 1273-81.

21. Kempf DJ, Klein C, Chen HJ, Klein LL, Yeung C, Randolph JT, Lau YY, et al. Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir. Antivir Chem Chemother 2007; 18: 163-7.

22. Garg V, Luo X, McNair L, van Heeswijk R, Kauffman R. Low-dose ritonavir and the pharmacokinetics of the investigational HCV protease inhibitor telaprevir in healthy volunteers (abstract 629). 18th Conference on Retroviruses and Opportunistic Infections, Feb 27-Mar 2, 2011, Boston, USA [Accessed 14 Aug 2011]. Available from: http:// www.retroconference.org/2011/Abstracts/40192.htm

23. Garg V, van Heeswijk R, Lee J, Alves K, Nadkarni P, Luo X. Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus. Hepatology 2011; 54: 20-17

24. Lam S, Partovi N, Ting LSL, Ensom MH. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction? Ann Pharmacother 2008; 42: 1037-47.

25. Lee J, van Heeswijk R, Alves K, Smith F, Garg V. Effect of the hepatitis C protease inhibitor telaprevir on the pharmacokinetics of amlodipine and atorvastatin. Antimicrob Agents Chemother 2011; Epub 8 Aug 2011. DOI: 10.1128/ AAC.00653-11.

26. Garg V, Yang Y, Smith F, et al. The pharmacokinetic interaction between an oral contraceptive containing ethinyl estradiol and norethindrone and telaprevir [abstract PK_17]. 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy, June 22-23, 2011, Cambridge, MA.